Literature DB >> 1346458

Control of emesis in bowel obstruction in terminally ill patients.

D Khoo, J Riley, J Waxman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1346458     DOI： 10.1016/0140-6736(92)91700-i

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Octreotide prevents the pathological alterations of bowel obstruction in cancer patients.

Authors:  S Mercadante; G Avola; S Maddaloni; G Salamone; F Aragona; V Rodolico
Journal:  Support Care Cancer       Date:  1996-09       Impact factor: 3.603

2.  Why not octreotide?

Authors:  S Mercadante
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

3.  Secretory symptoms from metastatic adrenal cortical carcinoma responding to octreotide.

Authors:  H S Pandha; K Harrington; S Saini; J Lynn; M Peters; J Waxman
Journal:  Postgrad Med J       Date:  1995-04       Impact factor: 2.401

4.  [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review].

Authors:  G Benze; A Geyer; B Alt-Epping; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.